What do systematic reviews say?

CHRONIC: Beta‐blockers vs placebo

CHRONIC: Beta‐blockers probably leads to lower death (any cause) ( compared with placebo (moderate certainty).

• Pharmacological interventions for heart failure in people with chronic kidney disease 2020 · Cochrane Headline outcomes only
  RR 0.69 [0.6, 0.79]
  4 studies · 3136 participants
  Moderate

CHRONIC: Beta‐blockers vs placebo

CHRONIC: Beta‐blockers may leads to lower cardiovascular death ( compared with placebo (low certainty).

• Pharmacological interventions for heart failure in people with chronic kidney disease 2020 · Cochrane Headline outcomes only
  RR 0.53 [0.35, 0.81]
  3 studies · 2287 participants
  Low

CHRONIC: Beta‐blockers vs placebo

CHRONIC: Beta‐blockers showed no clear difference in hospitalisation (any cause) compared with placebo (low certainty).

• Pharmacological interventions for heart failure in people with chronic kidney disease 2020 · Cochrane Headline outcomes only
  RR 0.75 [0.52, 1.08]
  2 studies · 1583 participants
  Low

CHRONIC: Beta‐blockers vs placebo

CHRONIC: Beta‐blockers showed no clear difference in heart failure hospitalisation ( compared with placebo (low certainty).

• Pharmacological interventions for heart failure in people with chronic kidney disease 2020 · Cochrane Headline outcomes only
  RR 0.67 [0.43, 1.05]
  3 studies · 2287 participants
  Low

CHRONIC: Beta‐blockers vs placebo

It is very uncertain whether CHRONIC: Beta‐blockers changes worsening heart failure compared with placebo (very low certainty).

• Pharmacological interventions for heart failure in people with chronic kidney disease 2020 · Cochrane Headline outcomes only
  RR 1.36 [0.58, 3.2]
  1 study · 704 participants
  Very low

CHRONIC: Beta‐blockers vs placebo

• Pharmacological interventions for heart failure in people with chronic kidney disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 704 participants
  Very low

CHRONIC: Beta‐blockers vs placebo

It is very uncertain whether CHRONIC: Beta‐blockers changes hypotension compared with placebo (very low certainty).

• Pharmacological interventions for heart failure in people with chronic kidney disease 2020 · Cochrane Headline outcomes only
  RR 5.11 [0.25, 106.15]
  1 study · 704 participants
  Very low

CHRONIC: Beta‐blockers vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for heart failure in people with chronic kidney disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

CHRONIC: Beta‐blockers vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for heart failure in people with chronic kidney disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Beta‐blockers vs placebo or no treatment

Beta‐blockers may leads to lower cardiovascular mortality (RR) compared with placebo or no treatment (low certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 0.78 [0.62, 0.99]
  3 studies · 1046 participants
  Low

Beta‐blockers vs placebo or no treatment

It is very uncertain whether beta‐blockers changes heart failure hospitalisation (RR) compared with placebo or no treatment (very low certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 0.73 [0.47, 1.13]
  4 studies · 449 participants
  Very low

Beta‐blockers vs placebo or no treatment

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 245 participants
  Very low

Beta‐blockers vs placebo or no treatment

Beta‐blockers showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (low certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 0.82 [0.67, 1]
  4 studies · 1105 participants
  Low

Beta‐blockers vs placebo or no treatment

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 93 participants
  Very low

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 511 participants
  Low

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (moderate certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 0.93 [0.61, 1.42]
  2 studies · 945 participants
  Moderate

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in heart failure hospitalisation (RR) compared with placebo or no treatment (moderate certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 0.86 [0.64, 1.15]
  3 studies · 1019 participants
  Moderate

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 74 participants
  Very low

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (moderate certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 1.04 [0.75, 1.45]
  5 studies · 1187 participants
  Moderate

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 154 participants
  Low